Study title: Asakura M, Ikegame K, Yoshihara S,Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H. 2010. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol. 2010 Sep;92(2):351-9.Asakura M, Ikegame K, Yoshihara S,Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H. 2010. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. Int J Hematol. 2010 Sep;92(2):351-9.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Virus Diseases [C02] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: FOSCARNET | |||||
| ATC code: | |||||
| Document link: Asakura M et al 2010.pdf | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Review Article | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |